Get a Quote

Dabigatran Etexilate Mesylate
CAS NO.: 872728-81-9
Chemical Formula: C34H41N7O5.CH4O3S
Molecular Weight: 723.8400
DMF&GMP status: Please contact us for more details.
Description:
Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
DABIGATRAN ETEXILATE MESYLATECAPSULE; ORALEQ 110MG BASEPRADAXABOEHRINGER INGELHEIM
DABIGATRAN ETEXILATE MESYLATE CAPSULE; ORAL EQ 150MG BASE PRADAXA BOEHRINGER INGELHEIM
DABIGATRAN ETEXILATE MESYLATE CAPSULE; ORAL EQ 75MG BASE PRADAXA BOEHRINGER INGELHEIM
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
608738018-Feb-18YYU - 1089
7866474 31-Aug-27   Y  
7932273 7-Sep-25 Y Y  
9034822 20-Jan-31     U - 1759
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 19-Oct-15
I – 682 4-Apr-17
I – 683 4-Apr-17
M - 168 20-Nov-18